Spectrum Pharmaceuticals announced that Fusilev (levoleucovorin for injection) has gained an indication in combination with 5-fluorouracil for the palliative treatment of patients with advanced metastatic colorectal cancer. Fusilev is already indicated for rescue after high-dose methotrexate therapy in osteosarcoma and is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists.

For more information call (877) FUSILEV or visit www.fusilev.com.